ANTICORPS MONOCLONAUX HUMAINS POUR MORT PROGRAMMEE 1 (MP-1) ET PROCEDES POUR TRAITER LE CANCER EN UTILISANT DES ANTICORPS ANTI-MP-1 SEULS OU ASSOCIES A D'AUTRES IMMUNOTHERAPIES
LTD.;ONO PHARMACEUTICAL CO.;ONO PHARMACEUTICAL CO., LTD.;MEDAREX, INC.
发明人:
KORMAN, ALAN J.,SRINIVASAN, MOHAN,WANG, CHANGYU,SELBY, MARK J.,CHEN, BING,CARDARELLI, JOSEPHINE M.,HUANG, HAICHUN
申请号：
CA2607147
公开号：
CA2607147C
申请日:
2006.05.02
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention provides isolated monoclonal antibodies, particularlyhuman monoclonal antibodies, that specifically bind to PD-1 with highaffinity. Nucleic acid molecules encoding the antibodies of the invention,expression vectors, host cells and methods for expressing the antibodies ofthe invention are also provided. Immunoconjugates, bispecific molecules andpharmaceutical compositions comprising the antibodies of the invention arealso provided. The invention also provides methods for detecting PD-1, as wellas methods for treating various diseases, including cancer and infectiousdiseases, using anti-PD-1 antibodies. The present invention further providesmethods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such ascancer. The invention also provides methods for altering adverse eventsrelated to treatment with such antibodies individually.
